Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC 98 3-Year EBITDA Growth Rate is 16.60% as of Jun. 2026, which is 50% above its 10-year median of 11.05. GuruFocus rates MIL:REC with a GF Score™ of 98/100 and a GF Value™ of €61.10 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Recordati SpA ranks better than 63.35% on this metric.
During the past 12 months, Recordati SpA's average EBITDA Per Share Growth Rate was 18.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 10.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Recordati SpA was 25.00% per year. The lowest was -1.40% per year. And the median was 11.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Recordati SpA 3-Year EBITDA Growth Rate Related Terms
MIL:REC vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Recordati SpA's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.60% mean?
Recordati SpA (MIL:REC) has a 3-Year EBITDA Growth Rate of 16.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Recordati SpA and its competitors. This is 50% above median its historical median of 11.05. According to the industry distribution chart, Recordati SpA ranks #298 out of 813 companies in the Drug Manufacturers industry, placing it in the top 36.7%.
Is Recordati SpA's 3-Year EBITDA Growth Rate too high?
Recordati SpA's current 3-Year EBITDA Growth Rate of 16.60% is 50% above median its 10-year median of 11.05. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Recordati SpA's value of 16.60% is 88.6% above this industry median. Based on the distribution chart, Recordati SpA ranks #298 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Recordati SpA has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #298 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Recordati SpA in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Recordati SpA's value of 16.60% is 88.6% above this benchmark. While the company's 10-year median is 11.05 vs. the industry median of 8.80, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current 3-Year EBITDA Growth Rate of 16.60% is 88.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Recordati SpA and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current 3-Year EBITDA Growth Rate is 16.60%, which is 50% above median its own 10-year median of 11.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €61.10, compared to a current price of €51.65 — trading 15.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.60%, which is 50% above median its 10-year median of 11.05 and 88.6% above the Drug Manufacturers industry median of 8.80. Recordati SpA's overall GF Score™ is 98/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current 3-Year EBITDA Growth Rate is 16.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.65 is trading 15.5% below its estimated GF Value™ of €61.10.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
3-Year EBITDA Growth Rate: 16.60% (50% above median its 10-year median of 11.05)
GF Value™: €61.10 vs. price of €51.65 (15.5% below fair value)
Industry Position: 88.6% above the Drug Manufacturers median (#298 of 813)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
98GF Score
Get the complete analysis for MIL:REC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
